Evelo is a clinical-stage biotech with a vision to dramatically improve healthcare. Our work aims to harness SINTAX to modulate the body’s immune system.
Employees: 51-200
Total raised: $50M
Founded date: 2014
Investors 5
| Date | Name | Website |
| - | K2 HealthV... | k2healthve... |
| - | SV Health ... | svhealthin... |
| - | K2 HealthV... | k2hv.com |
| - | Horizon Te... | horizontec... |
| - | GV | gv.com |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 13.07.2017 | Series B | $50M | - |
Mentions in press and media 18
| Date | Title | Description | Source |
| 12.07.2023 | Evelo Biosciences Closes $25.5 Million Private Placement | - | globenewsw... |
| 25.05.2022 | Evelo Biosciences Announces $79.2 Million Registered Direct ... | CAMBRIDGE, Mass., May 25, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinica... | globenewsw... |
| 28.10.2021 | Evelo Biosciences Reports Third Quarter 2021 Financial Resul... | –Positive Phase 2 clinical data with EDP1815 in psoriasis; moving towards registration studies– –Dos... | marketscre... |
| 28.10.2021 | Evelo Biosciences Reports Third Quarter 2021 Financial Resul... | Evelo Biosciences Reports Third Quarter 2021 Financial Results and Business Highlights -Positive Pha... | marketscre... |
| 09.03.2021 | EVELO BIOSCIENCES, INC. Evelo Biosciences : Announces Fourt... | –Announced new positive data in human experimental model of inflammation of EDP1815– –Completed enro... | marketscre... |
| 25.07.2019 | Evelo Biosciences Secures $45M Debt Financing from K2 Health... | CAMBRIDGE, Mass., July 25, 2019 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a biotec... | citybizlis... |
| 19.06.2018 | 15 Boston Microbiome Startups to Watch | “Bacteria, it’s the only culture some people have!” If you spot someone wearing a tee shirt with tha... | bizjournal... |
| 09.05.2018 | Evelo Bio grabs $85M as the latest early-stage biotech de... | Evelo Biosciences became the latest early-stage biotech company to make the leap into Nasdaq... | endpts.com... |
| 14.04.2018 | Flagship’s Evelo Biosciences pitches $100M IPO for a new ... | Simba Gill With its lead “monoclonal microbial” about to be tested for the first time on a hu... | endpts.com... |
| 08.08.2017 | Reality vs. hype: A macro look at the microbiome market | Silicon Valley Bank has gone a long way to answering that question with its recent report, titled: “... | medcitynew... |
Show more